Your fact-checks will appear here
Treatment options for type 2 diabetes, including berberine and metformin
A widely shared claim that “” appeared on “60 Minutes” endorsing a $1‑a‑day ritual that kills a parasite causing is false and grounded in misinformation: there is no evidence CBS’s “60 Minutes” ran su...
(also marketed as Glycopezil/GlycoPezil) is promoted online as a natural "blood sugar support" supplement that advertisers claim can reverse , but there is no credible evidence or verifiable clinical ...
A clear consensus does not exist: shows some evidence of modest blood‑glucose benefits in certain trials, while is a carbohydrate that can raise blood sugar despite possible lipid or weight effects, a...
Randomized placebo-controlled trials using oral at total daily doses of roughly 900–1,500 mg have repeatedly reported improvements in blood glucose control (including HbA1c or related glycemic measure...
A small but growing set of randomized trials—mostly early‑phase safety studies and a few larger community cluster trials—are registered or underway that directly test or the removal of helminths to pr...
A broad, evidence-based arsenal of FDA‑approved therapies exists for type 2 diabetes: lifestyle plus metformin remains the long‑standing first‑line approach, and pharmacologic options now include mult...
Metformin, GLP‑1 receptor agonists (GLP‑1RAs) and SGLT2 inhibitors all lower A1C but differ in magnitude and persistence: metformin provides modest, durable reductions and remains first‑line; GLP‑1RAs...
directly comparing berberine to metformin are few and small: the oft‑cited head‑to‑head pilot by randomized 36 newly diagnosed patients to for about three months and reported comparable glycemic reduc...
There is no universally accepted, single "" for diabetes today, but multiple promising, disease-modifying approaches are converging—especially for type 1 diabetes () via , gene and immune therapies, a...
Randomized clinical trials of chromium and alpha‑lipoic acid (ALA) have been conducted for decades, but the literature is mixed: multiple RCTs and meta‑analyses exist showing small or inconsistent eff...
Randomized controlled trials exist that directly compare berberine combined with metformin versus metformin alone, mostly small, short-duration studies conducted in China and pooled in recent meta-ana...
Bydureon (exenatide extended‑release) is a once‑weekly injectable GLP‑1 receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults and certai...